Abstract
Aim:
To improve the oral absorption of adefovir dipivoxil (ADV) by employing MCT and the esterase inhibitor ethyl oleate (EO) as a complex oil phase in emulsion.
Methods:
EO was used as the esterase inhibitor, and its inhibitory effect on esterase activity was assessed in rat intestinal homogenates. ADV emulsions with or without EO were prepared. The emulsions' protective effect against intestinal metabolism was evaluated in rat luminal contents, ex vivo, as well as in vivo.
Results:
The IC50 of EO in intestinal mucosal homogenates was 2.2 mg/mL. The emulsions exhibited significant protective effects in rat luminal contents compared to a simple suspension (98.7%, 96.3%, 95.7% vs 74.7%, P<0.01). The permeability calculated from the emulsion containing EO was significantly different (11.4×10−6 vs 7.4/8.0×10−6, P<0.05) from the simple suspension or the emulsion without EO in an ex vivo assay. A bioavailability study in vivo revealed that emulsions containing both EO and MCT as a complex oil phase demonstrated 1.6- and 1.5-fold enhancements in area under the curve (AUC0–12) values (5358 vs 3386/3618, P<0.05), respectively, when compared with emulsions containing EO or MCT as a single oil phase.
Conclusion:
Heterotic lipid formulations (emulsions) with an esterase inhibitor (ie, EO) may be useful in protecting ester prodrugs from intestinal metabolism and increasing their oral bioavailability.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Beaumont K, Webster R, Gardner I, Dack K . Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 2003; 4: 461–85.
Ettmayer P, Amidon GL, Clement B, Testa B . Lessons learned from marketed and investigational prodrugs. J Med Chem 2004; 47: 2393–404.
Testa B . Prodrug research: Futile or fertile? Biochem Pharmacol 2004; 68: 2097–106.
Bianca ML, Ronald TB . Enzymes Involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95: 1177–95.
Imai T . Human carboxylesterase isozymes: Catalytic properties and rational drug design. Drug Metab Pharmacokinet 2006; 21: 173–85.
Crauste-Manciet S, Huneau JF, Decroix MO, Farinotti R, Chaumeil JC . Cefpodoxime proxetil esterase activity in rabbit small intestine: a role in the partial cefpodoxime absorption. Int J Pharm 1997; 149: 241–9.
Annaert P, Kinget R, Naesens L, De Clercq E, Augustijns P . Transport, uptake, and metabolism of the bis (pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm Res 1997; 14: 492–6.
Crauste-Manciet S, Brossard D, Decroix MO, Farinotti R, Chaumeil JC . Cefpodoxime proxetil protection from intestine lumen hydrolysis by oil-in water submicron emulsions. Int J Pharm 1998; 165: 97–106.
Cao F, Guo JX, Ping QN, Liao ZG . Prodrugs of scutellarin: ethyl, benzyl and N,N-diethylglycolamide ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats. Eur J Pharm Sci 2006; 29: 385–93.
Brandt E, Heymann E, Mentlein R . Selective inhibition of rat liver carboxylesterases by various organophosphorus diesters in vivo and in vitro. Biochem Pharmacol 1980; 29: 1927–31.
Hyatt JL, Tsurkan L, Wierdl M, Edwards CC, Danks MK and Potter PM . Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity. Mol Cancer Ther 2006; 5: 2281–8.
Hyatt JL, Moak T, Hatfield MJ, Tsurkan L, Edwards CC, Wierdl M, et al. Selective Inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem 2007; 50: 1876–85.
Harada T, Nakagawa Y, Wadkins RM, Potter PM, Wheelock CE . Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis. Bio Org Med Chem 2009; 17: 149–64.
Van Gelder J, Annaert P, Naesens L, De Clercq E, Mooter GV, Kinget R, et al. Inhibition of Intestinal metabolism of the antiviral ester prodrug bis (poc)-PMEA by nature identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharm Res 1999; 16: 1035–40.
Augustijns P . Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 2000; 28: 1394–6.
Van Gelder J, Deferme S, Naesens L, De Clercq E, Mooter GV, Kinget R, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30: 924–30.
Maria F, Raza O . Case study: Adefovir dipivoxil: An oral prodrug of Adefovir. In: Biotechnology: Pharmaceutical Aspects v 5. Prodrugs: Challenges and Rewards. New York: Springer New York; 2008. p 1151–61.
Samira B, Helene P, Richard J, Georges M, Jean-Louis I, Anne-Marie A, et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J Med Chem 1996; 39: 4958–65.
Annaert P, Tukker JJ, Van Gelder J, Naesens L, De Clercq E, Van den Mooter G, et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. J Pharm Sci 2000; 89: 1054–62.
Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.
Van Gelder J, Shafiee M, De Clercq E, Penninckx F, Mooter GV, Kinget R, et al. Species-dependent and site-specific intestinal metabolism of ester prodrugs. Int J Pharm 2000; 205: 93–100.
Ren X, Mao X, Cao L, Xue K, Si L, Qiu J, et al. Nonionic surfactants are strong inhibitors of cytochrome P4503A biotransformation activity in vitro and in vivo. Eur J Pharm Sci 2009; 36: 401–11.
Dahan A, Hoffman A . Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res 2006; 23: 2165–74.
Dahan A, Hoffman A . The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm 2007; 67: 96–105.
Parsons DS, Paterson GR . Movement of fluid and glucose in an everted sac preparation of rat colonic mucosa. Biochim Biophys Acta 1960; 41: 173–5.
Jeng-Pyng S, Michael SL, Krishnamurthy VV, Murty NA, Robert JJ, Alison MB, et al. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab Dispos 1997; 25: 362–6.
Zhao LY, Chen XY, Zhang Y, Yang HY, Zhong DF . Determination of adefovir in monkey plasma by liquid chromatography-tandem mass spectrometry. Acta Pharm Sin 2003; 38: 120–3.
Sugiura S, Nakajima M, Yamamoto K, Iwamoto S, Oda T, Satake M, et al. Preparation characteristics of water-in-oil-in-water multiple emulsions using microchannel emulsification. J colloid interface sci 2004; 270: 221–8.
Yi T, Wan J, Xu H, Yang X . A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm 2008; 70: 439–44.
Michael L . Fatty acid ethyl esters: nonoxidative ethanol metabolites with emerging biological and clinical significance. Lipids 1999; 34: 281–5.
Kaphalia BS, Fritz RR, Ansari GAS . Purification and characterization of rat liver microsomal fatty acid ethyl and 2-chloroethyl ester synthase and their relationship with carboxylesterase. Chem Res Toxicol 1997; 10: 211–8.
Saghir M, Werner J, Laposata M . Rapid in vivo hydrolysis of fatty acid ethyl esters, toxic nonoxidative ethanol metabolites. Am J Physiol 1997; 273: 184–90.
Porter CJH, Trevaskis NL, Charman WN . Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6: 231–48.
Kenji M, Mitsuru H, Teruko I . Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum. Drug Metab Dispos 2007; 35: 1089–95.
Porter CJH, Pouton CW . Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Delivery Rev 2008; 60: 625–37.
Embleton JK, Pouton CW . Structure and function of gastro-intestinal lipases. Adv Drug Delivery Rev 1997; 25(1): 15–32.
Porter CJH, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA, et al. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J Pharm Sci 2004; 93: 1110–21.
Acknowledgements
This work was supported by the National Natural Sciences Foundation of China (No 30701054) and the National Science & Technology Major Project's Key New Drug Creation and Manufacturing Program (No 2009ZX09301-001). This work was also supported in part by the National Basic Research Program of China (No 2009CB930300).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, P., Yu, Hz., Zhang, Xx. et al. Absorption enhancement of adefovir dipivoxil by incorporating MCT and ethyl oleate complex oil phase in emulsion. Acta Pharmacol Sin 31, 881–888 (2010). https://doi.org/10.1038/aps.2010.60
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2010.60
